BRIEF-Cellectar wins EMA nod to seek conditional approval for Iopofosine in rare blood cancer

Reuters10-06

Oct 6 (Reuters) - Cellectar Biosciences Inc CLRB.O:

CELLECTAR BIOSCIENCES ANNOUNCES EUROPEAN MEDICINES AGENCY $(EMA)$ CONFIRMS ELIGIBILITY TO FILE FOR CONDITIONAL MARKETING AUTHORIZATION $(CMA)$ FOR IOPOFOSINE I 131 AS A TREATMENT FOR REFRACTORY (POST-BTKI) WALDENSTROM MACROGLOBULINEMIA $(WM)$
CELLECTAR BIOSCIENCES : POTENTIAL 2027 EUROPEAN APPROVAL AND COMMERCIAL LAUNCH OF IOPOFOSINE I 131 AS A TREATMENT FOR REFRACTORY (POST-BTKI) WM
CELLECTAR BIOSCIENCES INC - CMA APPLICATION FOR IOPOFOSINE I 131 EXPECTED IN EARLY 2026

Source text: ID:nGNX5Cgc9r

Further company coverage: CLRB.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2573794456?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-06 19:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573794456","market":"nz","top_or_hot":-1,"title":"BRIEF-Cellectar wins EMA nod to seek conditional approval for Iopofosine in rare blood cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Cellectar wins EMA nod to seek conditional approval for Iopofosine in rare blood cancer</title></head><body><p><span>Oct 6 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/CLRBZ\">Cellectar Biosciences</a> Inc <span>CLRB.O</span>:</p><ul><li><p>CELLECTAR BIOSCIENCES ANNOUNCES EUROPEAN MEDICINES AGENCY <a href=\"https://laohu8.com/S/EMA\">$(EMA)$</a> CONFIRMS ELIGIBILITY TO FILE FOR CONDITIONAL MARKETING AUTHORIZATION <a href=\"https://laohu8.com/S/CMA\">$(CMA)$</a> FOR IOPOFOSINE I 131 AS A TREATMENT FOR REFRACTORY (POST-BTKI) WALDENSTROM MACROGLOBULINEMIA <a href=\"https://laohu8.com/S/WM\">$(WM)$</a></p></li><li><p>CELLECTAR BIOSCIENCES : POTENTIAL 2027 EUROPEAN APPROVAL AND COMMERCIAL LAUNCH OF IOPOFOSINE I 131 AS A TREATMENT FOR REFRACTORY (POST-BTKI) WM</p></li><li><p>CELLECTAR BIOSCIENCES INC - CMA APPLICATION FOR IOPOFOSINE I 131 EXPECTED IN EARLY 2026</p></li></ul><p>Source text: <span>ID:nGNX5Cgc9r</span></p><p>Further company coverage: <span>CLRB.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Cellectar wins EMA nod to seek conditional approval for Iopofosine in rare blood cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Cellectar wins EMA nod to seek conditional approval for Iopofosine in rare blood cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-06 19:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Cellectar wins EMA nod to seek conditional approval for Iopofosine in rare blood cancer</title></head><body><p><span>Oct 6 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/CLRBZ\">Cellectar Biosciences</a> Inc <span>CLRB.O</span>:</p><ul><li><p>CELLECTAR BIOSCIENCES ANNOUNCES EUROPEAN MEDICINES AGENCY <a href=\"https://laohu8.com/S/EMA\">$(EMA)$</a> CONFIRMS ELIGIBILITY TO FILE FOR CONDITIONAL MARKETING AUTHORIZATION <a href=\"https://laohu8.com/S/CMA\">$(CMA)$</a> FOR IOPOFOSINE I 131 AS A TREATMENT FOR REFRACTORY (POST-BTKI) WALDENSTROM MACROGLOBULINEMIA <a href=\"https://laohu8.com/S/WM\">$(WM)$</a></p></li><li><p>CELLECTAR BIOSCIENCES : POTENTIAL 2027 EUROPEAN APPROVAL AND COMMERCIAL LAUNCH OF IOPOFOSINE I 131 AS A TREATMENT FOR REFRACTORY (POST-BTKI) WM</p></li><li><p>CELLECTAR BIOSCIENCES INC - CMA APPLICATION FOR IOPOFOSINE I 131 EXPECTED IN EARLY 2026</p></li></ul><p>Source text: <span>ID:nGNX5Cgc9r</span></p><p>Further company coverage: <span>CLRB.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CLRB","symbol_name":"Cellectar Biosciences Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nTUAHX56:1","article_id":"2573794456","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573794456","pubTimestamp":1759748953,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Cellectar wins EMA nod to seek conditional approval for Iopofosine in rare blood cancerOct 6 (Reuters) - Cellectar Biosciences Inc CLRB.O:CELLECTAR BIOSCIENCES ANNOUNCES EUROPEAN MEDICINES AGENC","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CLRB":"Cellectar Biosciences Inc.","BK4139":"生物科技"},"translate_title":"简介-Cellectar获得EMA批准，寻求有条件批准碘泊福新治疗罕见血癌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLRB":0.9},"content_text":"BRIEF-Cellectar wins EMA nod to seek conditional approval for Iopofosine in rare blood cancerOct 6 (Reuters) - Cellectar Biosciences Inc CLRB.O:CELLECTAR BIOSCIENCES ANNOUNCES EUROPEAN MEDICINES AGENCY $(EMA)$ CONFIRMS ELIGIBILITY TO FILE FOR CONDITIONAL MARKETING AUTHORIZATION $(CMA)$ FOR IOPOFOSINE I 131 AS A TREATMENT FOR REFRACTORY (POST-BTKI) WALDENSTROM MACROGLOBULINEMIA $(WM)$CELLECTAR BIOSCIENCES : POTENTIAL 2027 EUROPEAN APPROVAL AND COMMERCIAL LAUNCH OF IOPOFOSINE I 131 AS A TREATMENT FOR REFRACTORY (POST-BTKI) WMCELLECTAR BIOSCIENCES INC - CMA APPLICATION FOR IOPOFOSINE I 131 EXPECTED IN EARLY 2026Source text: ID:nGNX5Cgc9rFurther company coverage: CLRB.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2573794456","isCrawlerRequest":true}